Colorectal Cancer

Douglas A. Nelson, MD, discusses the future utility of circulating tumor DNA in colorectal cancer.

Tannaz Armaghany, MD, discusses the utility of circulating tumor DNA in colorectal cancer.

The European Commission has approved encorafenib (Braftovi) in combination with cetuximab (Erbitux) for the treatment of adult patients with BRAF V600E–mutant metastatic colorectal cancer who have received prior systemic therapy.

Scott Kopetz, MD, PhD, FACP, discusses the latest findings from the BEACON CRC study, the importance of testing for BRAF mutations in patients with CRC, and future directions with these agents.

Thierry Andre, MD, discusses the rationale for the phase 3 KEYNOTE-177 trial in metastatic colorectal cancer.

Michael J. Overman, MD, discusses potential applications for circulating tumor DNA in colorectal cancer.

Tanios S. Bekaii-Saab, MD, FACP, discusses the growing role of targeted therapy in CRC.

Fam-trastuzumab deruxtecan-nxki (Enhertu) demonstrated promising clinical activity in patients with HER2-positive metastatic colorectal cancer, as well as in those with HER2-positive advanced gastric or gastroesophageal junction adenocarcinoma.

AMG 510, a novel KRAS G12C inhibitor, demonstrated early evidence of a consistent safety profile and anticancer activity across a range of advanced KRAS G12C-mutant solid tumors other than non–small cell lung cancer and colorectal cancer.

Scott Kopetz, MD, PhD, FACP, discusses the updated survival data from the BEACON CRC study in BRAF V600E–mutated metastatic colorectal cancer.

Pembrolizumab doubled progression-free survival compared with chemotherapy in patients with newly diagnosed microsatellite instability–high/mismatch repair deficient metastatic colorectal cancer, according to findings from an interim analysis of the phase 3 KEYNOTE-177 trial.

The FDA has granted Fast Track designation to onvansertib for the second-line treatment of patients with KRAS-mutated metastatic colorectal cancer.

Jonathan Mizrahi, MD, discusses efforts being made to target treatment for patients with metastatic colorectal cancer.

Phat Le, MD, discusses research efforts that are needed to address unmet needs in metastatic colorectal cancer.

Kanwal Raghav, MBBS, MD, discusses the utility of circulating tumor DNA in colorectal cancer.

Douglas A. Nelson, MD, discusses why patients with metastatic colorectal cancer are often referred to surgeons before medical oncologists.

Van K. Morris, MD, discusses the role of immunotherapy in metastatic colorectal cancer.

Shai Friedland, MD, discusses the importance of screening for colorectal cancer, the advantages of the noninvasive FirstSightCRC blood test, and the results from the ZENITH trial.

Heinz-Josef Lenz, MD, FACP, discusses the next steps for the trial examining the onvansertib combination and sheds light on the possibility of this regimen eventually being used in the frontline setting.

Michael J. Overman, MD, professor in the Department of Gastrointestinal Medical Oncology of the Division of Cancer Medicine and committee vice chair at The University of Texas MD Anderson Cancer Center, discusses ongoing research with immunotherapy in microsatellite stable (MSS) colorectal cancer (CRC).

The combination of nivolumab and regorafenib demonstrated promising antitumor activity in patients with gastric and colorectal cancer.

Tanios S. Bekaii-Saab, MD, FACP, medical oncologist, medical director, Cancer Clinical Research Office, vice chair and section chief, Medical Oncology, Department of Internal Medicine, Mayo Clinic, discusses moving metastatic treatment strategies to the adjuvant setting in colorectal cancer (CRC).

A European panel has recommended approval of encorafenib in combination with cetuximab for the treatment of adult patients with BRAF V600E–mutant metastatic colorectal cancer.

The FDA has approved the combination of encorafenib and cetuximab for the treatment of adult patients with metastatic colorectal cancer with a BRAF V600E mutation, following prior therapy.

Frontline pembrolizumab significantly improved progression-free survival versus chemotherapy in patients with microsatellite instability–high or mismatch repair deficient unresectable or metastatic colorectal cancer.